Effect of heparin on neuroprotection against spinal cord ischemia and reperfusion in rats

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 4, 2013, Pages 522-530

  Korkmaz, K ^a   Gedik, H S ^a   Budak, A B ^a   Erdem, H ^b   Lafci, G ^c   Karakilic, E ^a   Nacar, O A ^a   Yildirim, L ^d   Ankarali, H ^b  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b DUZCE UNIVERSITY   (Turkey)

^c TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^d Sivas Numune Hospital   (Turkey)

Author keywords

Heparin; Ischemia and Reperfusion injury; Spinal cord

Indexed keywords

GLYCOSAMINOGLYCAN; HEAT SHOCK PROTEIN 70; HEPARIN; INTERLEUKIN 6; MYELOPEROXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; AORTA SURGERY; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; EDEMA; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LOW DRUG DOSE; LUMBAR SPINAL CORD; MALE; MOTOR DYSFUNCTION; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARAPLEGIA; PATIENT MONITORING; POSTOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL; RAT; REPERFUSION INJURY; SPINAL CORD ISCHEMIA; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; HEPARIN; HSP70 HEAT-SHOCK PROTEINS; INTERLEUKIN-6; MALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PEROXIDASE; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; SPINAL CORD; SPINAL CORD ISCHEMIA;

EID: 84878596251     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. SEREN M, BUDAK B, TURAN N, PARLAR AI, AKAR F, ULUS AT. Collaborative therapy with nebivalol and LNAME for spinal cord ischemia/reperfusion injury. Ann Vasc Surg 2008; 22: 425-31.
2. DUMONT RJ, OKONKWO DO, VERMA S, HURLBERT RJ, BOULOS PT, ELLEGALA DB, DUMONT AS. Acute spinal cord injury, part I: pathophysiologic mechanisms. Clin Neuropharmacol 2001; 24: 254-264.
3. SVENSSON LG, CRAWFORD ES, HESS KR, COSELLI JS, SAFI HJ. Experience with 1509 patients undergoing thoracoabdominal aortic operations. J Vasc Surg 1993; 17: 357-368; discussion 68-70.
4. MAUNEY MC, BLACKBOURNE LH, LANGENBURG SE, BUCHANAN SA, KRON IL, TRIBBLE CG. Prevention of spinal cord injury after repair of the thoracic or thoracoabdominal aorta. Ann Thorac Surg 1995; 59: 245-252.
5. INOKAWA H, DATE H, OKAZAKI M, OKUTANI D, AOKAGE K, NAGAHIRO I, AOE M, SANO Y, SHIMIZU N. Effects of postmortem heparinization in canine lung transplantation with non-heart-beating donors. J Thorac Cardiovasc Surg 2005; 129: 429-434.
6. ETZ CD, DI LUOZZO G, BELLO R, LUEHR M, KHAN MZ, BODIAN CA, GRIEPP RB, PLESTIS KA. Pulmonary complications after descending thoracic and thoracoabdominal aortic aneurysm repair: predictors, prevention, and treatment. Ann Thorac Surg 2007; 83: S870-876; discussion S90-92.
7. SEEKAMP A, WARREN JS, REMICK DG, TILL GO, WARD PA. Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury. Am J Pathol 1993; 143: 453-463.
8. BAO XQ, LIU GT. Bicyclol: a novel antihepatitis drug with hepatic heat shock protein 27/70-inducing activity and cytoprotective effects in mice. Cell Stress Chaperones 2008; 13: 347-355.
9. ZHANG K, ZHAO T, HUANG X, LIU ZH, XIONG L, LI MM, WU LY, ZHAO YQ, ZHU LL, FAN M. Preinduction of HSP70 promotes hypoxic tolerance and facilitates acclimatization to acute hypobaric hypoxia in mouse brain. Cell Stress Chaperones 2009; 14: 407-415.
10. LATCHMAN DS. Heat shock proteins and cardiac protection. Cardiovasc Res 2001; 51: 637-646.
11. MOSSER DD, CARON AW, BOURGET L, DENIS-LAROSE C, MASSIE B. Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. Mol Cell Biol 1997; 17: 5317-5327.
12. MOSSER DD, CARON AW, BOURGET L, DENIS-LAROSE C, MASSIE B. Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. Mol Cell Biol 1997; 17: 5317-5327.
13. FUJIBAYASHI T, HASHIMOTO N, JIJIWA M, HASEGAWA Y, KOJIMA T, ISHIGURO N. Protective effect of geranyl-geranylacetone, an inducer of heat shock protein 70, against drug-induced lung injury/fibrosis in an animal model. BMC Pulm Med 2009; 9: 45.
14. CHOUDHURY S, BAE S, KE Q, LEE JY, KIM J, KANG PM. Mitochondria to nucleus translocation of AIF in mice lacking Hsp70 during ischemia/reperfusion. Basic Res Cardiol. 2011; 106: 397-407.
15. QIAN M, EATON JW, WOLFF SP. Cyanate-mediated inhibition of neutrophil myeloperoxidase activity. Biochem J 1997; 326 (Pt 1): 159-166.
16. OLIVER WC. Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth 2009; 13: 154-175.
17. AHMED T, GARRIGO J, DANTA I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 1993; 329: 90-95.
18. EVANS RC, WONG VS, MORRIS AI, RHODES JM. Treatment of corticosteroid-resistant ulcerative colitis with heparin-a report of 16 cases. Aliment Pharmacol Ther 1997; 11: 1037-1040.
19. SEVERIN IC, SOARES A, HANTSON J, TEIXEIRA M, SACHS D, VALOGNES D, SCHEER A, SCHWARZ MK, WELLS TN, PROUDFOOT AE, SHAW J. Glycosaminoglycan analogs as a novel anti-inflammatory strategy. Front Immunol 2012; 3: 293.
20. TAIRA Y, MARSALA M. Effect of proximal arterial perfusion pressure on function, spinal cord blood flow, and histopathologic changes after increasing intervals of aortic occlusion in the rat. Stroke 1996; 27: 1850-1858.
21. GEDIK HS, KORKMAZ K, ERDEM H, KARAKILIC E, LAFCI G, ANKARALI H. Protective effect of heparin in the end organ ischemia/reperfusion injury of the lungs and heart. J Cardiothorac Surg 2012; 7: 123.
22. UMEHARA S, GOYAGI T, NISHIKAWA T, TOBE Y, MASAKI Y. Esmolol and landiolol, selective beta1-adrenoreceptor antagonists, provide neuroprotection against spinal cord ischemia and reperfusion in rats. Anesth Analg 2010; 110: 1133-1137.
23. SAHIN MA, ONAN B, GULER A, OZTAS E, UYSAL B, ARSLAN S, DEMIRKILIC U, TATAR H. Cilostazol, a type III phosphodiesterase inhibitor, reduces ischemia/reperfusion-induced spinal cord injury. Heart Surg Forum 2011; 14: E171-1777.
24. BUDAK B, SEREN M, TURAN NN, SAKAOGULLARI Z, ULUS AT. The protective effects of resveratrol and LNAME on visceral organs following aortic clamping. Ann Vasc Surg 2009; 23: 675-685.
25. HIRSH J, RASCHKE R, WARKENTIN TE, DALEN JE, DEYKIN D, POLLER L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995; 108(4 Suppl): 258S-275S.
26. DESPOTIS GJ, JOIST JH, HOGUE CW JR., ALSOUFIEV A, JOINER-MAIER D, SANTORO SA, SPITZNAGEL E, WEITZ JI, GOODNOUGH LT. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996; 76: 902-908.
27. BAIRD CW, ZURAKOWSKI D, ROBINSON B, GANDHI S, BURDIS-KOCH L, TAMBLYN J, MUNOZ R, FORTICH K, PIGULA FA. Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival. Ann Thorac Surg 2007; 83: 912-919; discussion 9-20.
28. MARTINDALE SJ, SHAYEVITZ JR, D'ERRICO C. The activated coagulation time: suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery. J Cardiothorac Vasc Anesth 1996; 10: 458-463.
29. UENO T, FURUKAWA K, KATAYAMA Y, SUDA H, ITOH T. Spinal cord protection: development of a paraplegia-preventive solution. Ann Thorac Surg 1994; 58: 116-120.
30. HIRSH J, WARKENTIN TE, SHAUGHNESSY SG, ANAND SS, HALPERIN JL, RASCHKE R, GRANGER C, OHMAN EM, DALEN JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119(1 Suppl): 64S-94S.